CytoReason said it plans to present insights on the top drug targets to provide new therapeutic options for IBD patients.

Drug development company BiolineRX announced that it has received approval from Israel’s Ministry of Health to commence a Phase II trial of its treatment for inflammatory bowel disease (IBD). The company reported that the Phase II trial will be an open-label study to evaluate the efficacy, safety and tolerability of the treatment, BL-7040, in up […]